Lipodystrophic Syndromes and Hyperlipidemia in a Cohort of HIV-1–Infected Patients Receiving Triple Combination Antiretroviral Therapy With a Protease Inhibitor
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (5) , 443-449
- https://doi.org/10.1097/00042560-200108150-00004
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Development of Cervical Fat Pads Following Therapy with Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Severe premature coronary artery disease with protease inhibitorsThe Lancet, 1998
- Indinavir-associated lipodystrophyAIDS, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998